JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Incremental Expression of 14-3-3 Protein Beta/Alpha in Urine Correlates with Advanced Stage and Poor Survival in Patients with Clear Cell Renal Cell Carcinoma
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Incremental Expression of 14-3-3 Protein Beta/Alpha in Urine Correlates with Advanced Stage and Poor Survival in Patients with Clear Cell Renal Cell Carcinoma
Kaneko, Shiho; Matsumoto, Kazumasa; Minamida, Satoru; Hirayama, Takahiro; Fujita, Tetsuo; Kodera, Yoshio; Iwamura, Masatsugu;
  PDF(new window)
 Abstract
We investigated the urinary levels of 14-3-3 protein beta/alpha to evaluate their diagnostic significance with regard to clear cell renal cell carcinoma (ccRCC) and angiomyolipoma (AML). Urine samples from 91 patients with ccRCC, 16 patients with AML and 24 healthy volunteers were assessed. We used an enzyme-linked immunosorbent assay (ELISA) to quantify 14-3-3 protein beta/alpha levels in urine. Values were higher in patients with ccRCC than in those with AML and in healthy volunteers. High levels were associated with pathologic stage, lymph node status, distant metastasis and poor survival. Urinary levels of 14-3-3 protein beta/alpha were significantly increased in patients with small-sized carcinoma, irrespective of being less than 4.0 cm and 2.0 cm, compared with levels in patients with AML. This study is the first to report that increased expression of 14-3-3 protein beta/alpha in urine is associated with advanced stage and poor survival in patients with ccRCC. In addition, urinary 14-3-3 protein beta/alpha may differentiate AML from RCC, even when small sized. These results suggest that examination of urinary 14-3-3 protein beta/alpha could serve as a diagnostic and prognostic marker in patients with ccRCC.
 Keywords
14-3-3 protein beta/alpha;renal cell carcinoma;diagnosis;ELISA;
 Language
English
 Cited by
 References
1.
Aitken A (1996). 14-3-3 and its possible role in co-ordinating multiple signaling pathways. Trends Cell Biol, 6, 341-7. crossref(new window)

2.
Amato RJ (2005). Renal cell carcinoma: review of novel single agent therapeutics and combination regimens. Ann Oncol, 16, 7-15. crossref(new window)

3.
Bissler JJ, Kingswood JC (2004). Renal angiomyolipomata. Kidney Int, 66, 924-34. crossref(new window)

4.
Frank I, Blute ML, Cheville JC, et al (2003). Solid renal tumors: an analysis of pathological features related to tumor size. J Urol, 170, 2217-20. crossref(new window)

5.
Fu H, Subramanian RR, Masters SC (2000). 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol, 40, 617-47. crossref(new window)

6.
Greene FL, Page DL, Fleming ID, et al (2002). AJCC Cancer Staging Manual, 6th edn. Springer, New York.

7.
Jinzaki M, Tanimoto A, Narimatsu Y, et al (1997). Angiomyolipoma: imaging findings in lesions with minimal fat. Radiol, 205, 497-502. crossref(new window)

8.
Liou JY, Wu CC, Chen BR, et al (2008). Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-delta transcriptional pathway. Mol Pharmacol, 74, 1399-1406. crossref(new window)

9.
Lipworth L, Tarone RE, McLaughlin JK (2006). The epidemiology of renal cell carcinoma. J Urol, 176, 2353-8. crossref(new window)

10.
Liu TA, Jan YJ, Ko BS, et al (2011). Increased expression of 14-3-3 ${\beta}$ promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. Am J Pathol, 179, 2698-708. crossref(new window)

11.
Lowrance WT, Ordonez J, Udaltsova N, et al (2014). CKD and the risk of incident cancer. J Am Soc Nephrol, 25, 2327-34 crossref(new window)

12.
Masakazu W, Mitsuru M, Kazuya M, et al (2014). Risk Factors for Renal Cell Carcinoma in a Japanese Population. Asian Pac J Cancer Prev, 15, 9065-70. crossref(new window)

13.
Matsuura K, Nakada C, Mashio M, et al (2011). Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC Cancer, 11, 523-32. crossref(new window)

14.
Mhawech P (2005). 14-3-3 proteins-an update. Cell Res, 15, 228-236. crossref(new window)

15.
Morrison DK (2009). The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol, 19, 16-23. crossref(new window)

16.
Mues AC, Palacios JM, Haramis G, et al (2010). Contemporary experience in the management of angiomyolipoma. J Endourol, 24, 1883-6. crossref(new window)

17.
Musholt TJ, Brehm C, Hanack J, et al (2006). Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1. J Surg Res, 131, 15-25. crossref(new window)

18.
Ngo TC, Wood CG, Karam JA (2014). Biomarkers of renal cell carcinoma. Urol Oncol, 32, 243-51. crossref(new window)

19.
Nguyen MM, Gill IS, Ellison LM (2006). The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results Program. J Urol, 176, 2397-400. crossref(new window)

20.
Patil S, Ishill N, Deluca J, et al (2010). Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients. Cancer, 116, 347-54. crossref(new window)

21.
Qi W, Liu X, Qiao D, et al (2005). Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int J Cancer, 113, 359-63. crossref(new window)

22.
Satoru M, Masatsugu I, Yoshio K, et al (2011). 14-3-3 Protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid. Anal Bioanal Chem, 401, 245-52. crossref(new window)

23.
Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29. crossref(new window)

24.
Sugiyama A, Miyagi Y, Komiya Y, et al (2003). Forced expression of antisense14-3-3beta RNA suppresses tumor cell growth in vitro and in vivo. Carcinogenesis, 24, 1549-59. crossref(new window)

25.
Takihara Y, Matsuda Y, Hara J (2000). Role of the beta isoform of 14-3-3 proteins in cellular proliferation and oncogenic transformation. Carcinogenesis, 21, 2073-7. crossref(new window)

26.
Washio M, Mori M, Mikami K, et al (2013). Cigarette smoking and other risk factors for kidney cancer death in a Japanese population: Japan collaborative cohort Study for Evaluation of Cancer Risk (JACC study). Asian Pac J Cancer Prev, 14, 6523-8. crossref(new window)

27.
Wei C, Lai YQ, Li XX,Ye JX (2013). TGF-beta-activated kinase-1: a potential prognostic marker for clear cell renal cell carcinoma. Asian Pac J Cancer Prev, 14, 315-20. crossref(new window)

28.
Weiss RH, Lin PY (2006). Kidney cancer: identification of novel targets for therapy. Kidney Int, 69, 224-32. crossref(new window)

29.
Wen RM, Zhang YJ, Ma S, et al (2015). Preoperative neutrophil to lymphocyte ratio as a prognostic factor in patients with non-metastatic renal cell carcinoma. Asian Pac J Cancer Prev, 16, 3703-8. crossref(new window)

30.
Wu Q, Liu CZ, Tao LY, et al (2012). The clinicopathological and prognostic impact of 14-3-3 protein isoforms expression in human cholangiocarcinoma by immunohistochemistry. Asian Pac J Cancer Prev, 13, 1253-9. crossref(new window)

31.
Yang X, Cao W, Lin H, et al (2009). Isoform-specific expression of 14-3-3 proteins in human astrocytoma. J Neurol Sci, 276, 54-9. crossref(new window)

32.
Yu ZH, Zhang Q, Wang YD, et al (2013). Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma. Asian Pac J Cancer Prev, 14, 3729-4. crossref(new window)

33.
Zhao J, Meyerkord CL, Du Y, et al (2011). 14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol, 22, 705-12. crossref(new window)